PARIS (Thomson Financial) - Vivalis said it has granted Acambis rights to
its eb66 cell line, derived from avian embryonic stem cells, to evaluate the
line as a production platform of viral vectors and vaccines.
Terms of the agreement were not disclosed.
"With already more than 30 different vaccines evaluated or developed on
Vivalis eb66 cell line, we strongly believe that this cell line has the
potential to become a standard cell substrate for vaccines production in the
foreseeable future", Franck Grimaud, Vivalis CEO, said in a statement.
Andrew Newby; Andrew.Newby@thomsonreuters.com
an/jfr
COPYRIGHT
Copyright Thomson Financial News Limited 2008. All rights reserved.
The copying, republication or redistribution of Thomson Financial News Content,
including by framing or similar means, is expressly prohibited without the prior
written consent of Thomson Financial News.
|